West Pharmaceutical Services, Inc. (WST) Expected to Post Quarterly Sales of $415.53 Million

Equities analysts forecast that West Pharmaceutical Services, Inc. (NYSE:WST) will report sales of $415.53 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for West Pharmaceutical Services’ earnings. The lowest sales estimate is $411.50 million and the highest is $418.00 million. West Pharmaceutical Services reported sales of $382.30 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 8.7%. The firm is expected to report its next quarterly earnings results on Thursday, February 15th.

On average, analysts expect that West Pharmaceutical Services will report full-year sales of $415.53 million for the current fiscal year. For the next financial year, analysts anticipate that the company will post sales of $1.73 billion per share, with estimates ranging from $1.71 billion to $1.74 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.14. West Pharmaceutical Services had a return on equity of 14.47% and a net margin of 12.12%. The firm had revenue of $398.20 million during the quarter, compared to the consensus estimate of $386.02 million. During the same period in the prior year, the firm earned $0.53 EPS. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year.

A number of research firms have weighed in on WST. Stephens began coverage on shares of West Pharmaceutical Services in a research report on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 price objective for the company. Zacks Investment Research raised shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Wednesday, September 27th. Wells Fargo & Company upped their price objective on shares of West Pharmaceutical Services from $105.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Bank of America cut shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective for the company. in a research report on Tuesday, October 17th. Finally, Jefferies Group raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and upped their price objective for the company from $96.00 to $115.00 in a research report on Friday, September 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $106.00.

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of West Pharmaceutical Services by 1.8% during the second quarter. Vanguard Group Inc. now owns 6,555,351 shares of the medical instruments supplier’s stock worth $619,612,000 after purchasing an additional 114,507 shares during the last quarter. BlackRock Inc. lifted its holdings in West Pharmaceutical Services by 7.1% in the second quarter. BlackRock Inc. now owns 6,217,894 shares of the medical instruments supplier’s stock worth $587,715,000 after acquiring an additional 412,858 shares during the last quarter. State Street Corp lifted its holdings in West Pharmaceutical Services by 2.8% in the second quarter. State Street Corp now owns 2,511,108 shares of the medical instruments supplier’s stock worth $237,351,000 after acquiring an additional 67,937 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in West Pharmaceutical Services by 10.1% in the second quarter. Goldman Sachs Group Inc. now owns 935,685 shares of the medical instruments supplier’s stock worth $88,441,000 after acquiring an additional 86,022 shares during the last quarter. Finally, Hermes Investment Management Ltd. lifted its holdings in West Pharmaceutical Services by 3.3% in the third quarter. Hermes Investment Management Ltd. now owns 908,655 shares of the medical instruments supplier’s stock worth $87,467,000 after acquiring an additional 28,955 shares during the last quarter. 93.28% of the stock is currently owned by institutional investors and hedge funds.

Shares of West Pharmaceutical Services (WST) traded up $0.10 during midday trading on Friday, reaching $99.49. The company had a trading volume of 278,988 shares, compared to its average volume of 363,203. West Pharmaceutical Services has a 52-week low of $77.97 and a 52-week high of $103.36. The firm has a market cap of $7,359.21, a P/E ratio of 42.72, a P/E/G ratio of 2.11 and a beta of 1.11. The company has a current ratio of 2.59, a quick ratio of 1.87 and a debt-to-equity ratio of 0.15.

ILLEGAL ACTIVITY WARNING: This news story was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/12/05/west-pharmaceutical-services-inc-wst-expected-to-post-quarterly-sales-of-415-53-million.html.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply